<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 10-K/A
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1996 COMMISSION FILE NUMBER 0-19373
--------------------
BIOMATRIX, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
DELAWARE (201) 945-9550 13-3058261
(State of other jurisdiction of (Registrant's telephone number, (IRS Employer
incorporation or organization) including area code) Identification No.)
</TABLE>
65 Railroad Avenue
Ridgefield, N.J. 07657
(Address of principal executive offices) (Zip Code)
--------------------
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
None
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
Common Stock. $.0001 Par Value
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act 1934
during preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No_______
------ ------
Indicate by check mark if disclosure of delinquent filers pursuant to
Item-405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K [ ].
The aggregate market value of the voting stock held by non-affiliates
of the registrant as of March 1, 1997, was approximately $106,105,870, based
upon the last reported sales price of the registrant's Common Stock on the
NASDAQ National Market System.
At March 1, 1997 there were 10,755,644 shares of the registrant's
Common Stock outstanding.
--------------------
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Proxy Statement relating to the Annual Meeting of
Shareholders to be held on May 29, 1997, are incorporated by reference into Part
III of this report. Other documents incorporated by reference are listed in the
Exhibit Index.
<PAGE> 2
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
LIST OF FINANCIAL STATEMENTS
See page F-1 of this Report, which includes an index to consolidated
financial statements.
LIST OF FINANCIAL STATEMENT SCHEDULES
None.
LIST OF EXHIBITS (numbered in accordance with Item 601 of Regulations S-K)
*3.1 Amended and Restated Certificate of Incorporation of Biomatrix,
Inc. as filed as an Exhibit to Registration No. 33-41424, and
incorporated herein by reference thereto.
*3.2 Amended and Restated Bylaws of the Company as filed as an Exhibit
to Registration No. 33-41424, and incorporated herein by reference
thereto.
*4 Specimen Stock Certificate as filed as an Exhibit to Registration
No. 33-41424, and incorporated herein by reference thereto.
*10.1 Distributor Agreement dated April 1, 1986 between Biomatrix, Inc.
and Union Carbide Chemicals and Plastics Corporation, Specialty
Chemicals Division, assigned to Amerchol Corporation on October 1,
1986, as amended as of April 1, 1991, as filed as an Exhibit to
Registration No. 33-41424, and incorporated herein by reference
thereto.
*10.2 Stock Purchase Agreement dated June 21, 1991 by and among
Biomatrix, Inc., Biomatrix Medical Canada Inc. and Investment Fund
in Biotechnology Biocapital Limited Partnership, as filed as an
Exhibit to Registration No. 33-41424, and incorporated herein by
reference thereto.
<PAGE> 3
*10.3 Shareholders Agreement dated June 21, 1991 between Biomatrix,
Inc., Biomatrix Medical Canada Inc. and Investment Fund in
Biotechnology Biocapital Limited Partnership, as filed as an
Exhibit to Registration No. 33-41424, and incorporated herein by
reference thereto.
*10.4 Technology License Agreement dated as of June 21, 1991 between
Biomatrix, Inc. and Biomatrix Medical Canada Inc. as filed as an
Exhibit to Registration No. 33-41424, and incorporated herein by
reference thereto.
*10.5 Management Services Agreement dated as of June 21, 1991 between
Biomatrix, Inc. and Biomatrix Medical Canada Inc. as filed as an
Exhibit to Registration No. 33-41424, and incorporated herein by
reference thereto.
*10.6 Consulting Agreement dated March 10, 1988 between Biomatrix, Inc.,
and Charles Weiss, M.D. as filed as an Exhibit to Registration No.
33-41424, and incorporated herein by reference thereto.
*10.7 Employment Agreement dated December 30, 1988 between Biomatrix,
Inc. and Endre A. Balazs, M.D. As filed as an Exhibit to
Registration No. 33-41424, and incorporated herein by reference
thereto. Management contract or compensatory plan required to be
filed as an exhibit to this form pursuant to Item 14(c) of this
report.
*10.8 Development Agreement by and among Biomatrix, Inc., Biomatrix
Svenska AB and OA Investor KB (Up-Will) dated February, 1990 as
filed as an Exhibit to Registration No. 33-41424, and incorporated
herein by reference thereto.
*10.9 1984 Stock Option Plan (as amended), and forms of Incentive and
Non-Statutory Stock Option Agreements. As filed as an Exhibit to
Registration No. 33-41424, and incorporated herein by reference
thereto. Management contract or compensatory plan required to be
filed as an exhibit to this form pursuant to Item 14(c) of this
report.
*10.10 Forms of Employment and Confidentiality Agreements, as filed as an
Exhibit to Registration No. 33-41424, and incorporated herein by
reference thereto.
*10.11 Distributorship Agreement dated January 1, 1991 between Biomatrix,
Inc. and Equinord KB, as filed as an Exhibit to Registration No.
33-41424, and incorporated herein by reference thereto.
*10.12 Lease dated June 1, 1992 between Biomatrix, Inc. and Safer
Development & Management Corp. for lease of premises located at 65
Railroad Avenue, Ridgefield, New Jersey, as filed as an Exhibit to
the 1992 annual report on Form 10-K, and incorporated herein by
reference thereto.
*10.13 Technology and License Agreement dated June 26, 1991 between
Biomatrix, Inc. and Union Carbide Corporation, as amended as of
October 3, 1986, as filed as an Exhibit to Registration No.
33-41424, and incorported herein by reference thereto.
*10.14 License Agreements dated as of May 21, 1982 by and between
Biomatrix, Inc. and each of Drs. Endre A. Balazs, Janet L.
Denlinger and Gerald S. Lazarus, as filed as an Exhibit to
Registration No. 33-41424, and incorporated herein by reference
thereto.
*10.15 Amendment to Employment Agreement dated December 30, 1988 between
Biomatrix, Inc. and Endre A. Balazs, M.D., as filed as an Exhibit
to the 1992 annual reports on Form 10-K, and incorporated herein
by reference thereto. Management contract or compensatory plan
required to be filed as an exhibit to this form pursuant to Item
14(c) of this report.
*10.16 Retirement Plan Agreement dated July 1, 1992 between Biomatrix,
Inc. and the trustees of the Company, as filed as an Exhibit to
the 1992 annual reports on Form 10-K, and incorporated herein by
<PAGE> 4
reference thereto. Management contract or compensatory plan
required to be filed as an exhibit to this form pursuant to Item
14(c) of this report.
*10.17 Distribution agreement dated November 9, 1993 between Biomatrix,
Inc. and Syntex Pharmaceuticals International Limited, as filed as
an Exhibit to the 1993 annual reports on Form 10-K, and
incorporated herein by reference thereto. (Confidential portions
have been filed separately with the Commission.)
*10.18 Loan Agreement between Biomatrix Medical Canada Inc. and Society
de Development Industrial du Quebec, as filed as an Exhibit to the
1993 annual reports on Form 10-K, and incorporated herein by
reference thereto.
*10.19 Consulting Agreement dated June 1, 1993 between Biomatrix, Inc.
and Julius A. Vida, Ph.D., as filed as an Exhibit to the quarterly
report on Form 10-Q for the quarter ended June 30, 1993, and
incorporated herein by reference thereto. Management contract or
compensatory plan required to be filed as an exhibit to this form
pursuant to Item 14(c) of this report.
*10.20 Stock Purchase Agreement dated June 23, 1994 between Biomatrix,
Inc. and Syntex Pharmaceuticals International Limited, as filed as
an Exhibit to the quarterly report on Form 10-Q for the quarter
ended June 30, 1994, and incorporated herein by reference thereto.
*10.21 Second Distribution Agreement dated June 23, 1994 between
Biomatrix, Inc. and Syntex Pharmaceuticals International Limited,
as filed as an Exhibit to the quarterly report on Form 10-Q for
the quarter ended June 30, 1994, and incorporated herein by
reference thereto. (Confidential portions have been filed
separately with the Commission.)
*10.22 Distribution Agreement dated March 17, 1995, between Biomatrix,
Inc. and Recordati Chimica e. Farmaceutica S.p.A., as filed as an
Exhibit to the quarterly report on Form 10-Q for the quarter ended
March 31, 1995, and incorporated herein by reference thereto.
(Confidential portions have been filed separately with the
Commission.)
*10.23 Stock Purchase Agreement dated March 17, 1995, between Biomatrix,
Inc. and Recordati Chimica e. Farmaceutica S.p.A., as filed as an
Exhibit to the quarterly report on Form 10-Q for the quarter ended
March 31, 1995, and incorporated herein by reference therto.
*10.24 Distribution Agreement dated September 8, 1995, between Biomatrix
Medical Canada Inc. and RhUne-Poulenc Rorer Canada Inc., as filed
as an Exhibit to the quarterly report on Form 10-Q for the quarter
ended September 30, 1995, and incorporated herein by reference
thereto. (Confidential portions have been filed separately with
the Commission.)
*10.25 Agreement dated August 29, 1995, between Biomatrix, Inc. and Rory
B. Riggs, as filed as an Exhibit to the quarterly report on Form
10-Q for the quarter ended September 30, 1995, and incorporated
herein by reference thereto.
*10.26 Stock Purchase Agreement dated July 11, 1995, between Biomatrix,
Inc. and Rory B. Riggs, as filed as an Exhibit to the quarterly
report on Form 10-Q for the quarter ended September 30, 1995, and
incorporated herein by reference thereto.
*10.27 Promissory Note from Rory B. Riggs to Biomatrix, Inc., as filed as
an Exhibit to the quarterly report on Form 10-Q for the quarter
ended September 30, 1995, and incorporated herein by reference
thereto.
*10.28 Amendment dated July 10, 1995, to the Consulting Agreement dated
June 1, 1993 between Biomatrix, Inc. and Julius A. Vida, as filed
as an Exhibit to the quarterly report on Form 10-Q for the quarter
ended September 30, 1995 , and incorporated herein by reference
therto. Management contract or compensatory plan required to be
filed as an exhibit to this form pursuant to Item 14(c) of this
report.
<PAGE> 5
*10.29 1994 Stock Option Plan. Filed as an exhibit to the Company's proxy
statement filed pursuant to Rule 14a-6 dated June 7, 1994, as
filed as an Exhibit to the 1995 Annual Reports on Form 10-K, and
incorporated herein by reference thereto.
*10.30 Non-employee director stock option plan. Filed as an exhibit to
the Company's proxy statement filed pursuant to Rule 14a-6 dated
May 23, 1995, as filed as an Exhibit to the 1995 Annual Reports on
Form 10-K, and incorported herein by reference thereto.
*10.31 United States Distribution Agreement dated June 14, 1996 between
Biomatrix, Inc. and Collagen Corporation, as filed as an Exhibit
to the quarterly report on Form 10-Q for the quarter ended June
30, 1996 and incorporated herein by reference thereto.
(Confidential treatment requested. Confidential portions have been
omitted and filed separately with the Commission.)
*10.32 Restated Distribution Agreement between Biomatrix, Inc. and Syntex
Pharmaceuticals International Limited dated April 9, 1996, as
filed as an Exhibit to the quarterly report on Form 10-Q for the
quarter ended June 30, 1996, and incorported herein by reference
thereto. (Confidential treatment requested. Confidential portions
have been omitted and filed separately with the Commission.)
*10.33 First Amendment to Stock Purchase Agreement, date April 7, 1996,
between Biomatrix, Inc. and Syntex Pharmaceuticals International
Limited, as filed as an Exhibit to the quarterly report on Form
10-Q for the quarter ended June 30, 1996, and incorporated herein
by reference thereto. (Confidential treatment requested.
Confidential portions have been omitted and filed separately with
the Commission.)
*10.34 Agreement of Lease, dated April 18, 1996, between Ridgefield
Associates and Biomatrix, Inc., as filed as an Exhibit to the
quarterly report on Form 10-Q for te quarter ended June 30, 1996,
and incorporated herein by reference thereto. (Confidential
treatment requested. Confidential portions have been omitted and
filed separately with the Commission.)
*10.35 International Distribution Agreement, dated June 14, 1996, between
Biomatrix, Inc. and Collagen Corporation, as filed as an Exhibit
to the quarterly report on Form 10-Q for the quarter ended June
30, 1996, and incorporated herein by reference thereto.
(Confidential treatment requested. Confidential portions have been
omitted and filed separately with the Commission.)
*10.36 Employment Agreement, dated April 2, 1996, between Biomatrix, Inc.
and Rory B. Riggs, as filed as an Exhibit to the quarterly report
on Form 10-Q for the quarter ended June 30, 1996, and incorporated
herein by reference thereto.
*10.37 Amendment dated March 31, 1996 to the Consulting Agreement, dated
June 1, 1993, between Biomatrix Inc. and Julius A. Vida, as filed
as and Exhibit to the quarterly report on Form 10-Q for the
quarted ended June 30, 1996, and incorporated herein by reference
thereto.
*10.38 Restricted Stock Purchase Agreement, date April 2, 1996, between
Biomatrix, Inc. and Rory B. Riggs, as filed as an Exhibit to the
Schedule 13D of Rory B. Riggs filed with the Commission on June
24, 1996 and incorporated herein by reference thereto.
*10.39 Secured Promissory Note, dated April 2, 1996, by Rory B. Riggs and
Biomatrix Inc., as filed as an Exhibit to the Schedule 13D of Rory
B. Riggs filed with the Commission on June 24, 1996 and
incorporated herein by reference thereto.
*10.40 Stock Pledge Agreement, dated April 2, 1996, between Rory B. Riggs
and Biomatrix Inc., as filed as an Exhibit to the Schedule 13D of
Rory B. Riggs filed with the Commission on June 24, 1996 and
incorporated herein by reference thereto.
<PAGE> 6
10.41 Distribution Agreement dated December 17, 1996, between Biomatrix,
Inc. and Boehringer Ingelheim France, S.A. (Confidential treatment
requested. Confidential portions have been omitted and filed
separately with the Commission.)
*11 Computation of Earnings per Share.
*21 List of Subsidiaries, as filed as an Exhibit to Registration No.
33-41424, and incorporated herein by reference thereto.
*23.1 Consent of Coopers & Lybrand L.L.P., independent auditors of the
Company.
*27.1 Financial Data Schedule.
------------------
REPORT ON FORM 8-K
* Incorporated by reference to the Registrant's annual report on Form 10-K
filed with the Securities and Exchange Commission on March 31, 1997.
<PAGE> 7
DATE: November 24, 1998
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this amended report to be signed on its
behalf by the undersigned thereunto duly authorized.
BIOMATRIX, INC.
/s/ RORY B. RIGGS
By:--------------------
Rory B. Riggs
President
<PAGE> 1
DISTRIBUTION AGREEMENT
THIS DISTRIBUTION AGREEMENT (this "Agreement") is made as of the 17th
day of December 1996 by and between BIOMATRIX, INC., a Delaware corporation
having its principal office at 65 Railroad Avenue, Ridgefield, New Jersey 07657,
U.S.A. ("Biomatrix") and BOEHRINGER INGELHEIM FRANCE, S.A., a French corporation
with its registered office at 37-39, Rue Boissiere, 75116 Paris, France (the
"Distributor").
WHEREAS, Biomatrix is engaged in the development and manufacture of the
Agreement Product (as hereinafter defined);
WHEREAS, the Distributor desires to enter into a distribution agreement
and be appointed the distributor of the Agreement Product in the Territory (as
hereinafter defined), and Biomatrix is willing to so appoint the Distributor;
and
WHEREAS, the Distributor desires to purchase from Biomatrix, and
Biomatrix desires to sell to the Distributor, the Distributor's requirements of
the Agreement Product in the Territory on the terms and subject to the
conditions set forth herein.
NOW, THEREFORE, in consideration of the premises and of the mutual
covenants of the parties hereto, it is hereby agreed as follows:
1. DEFINITIONS
In this Agreement, the following words and expressions shall have the
following meanings:
1.1. "Affiliate" shall mean, with respect to either party, any Person
that, directly or indirectly, is controlled by, controls or is under common
control with such party. For purposes of this definition, the term "control"
(including with correlative meanings, the terms "controlled by" and "under
common control with") shall mean, with respect to any Person, the direct or
indirect ownership of more than fifty percent (50%) of the voting or income
<PAGE> 2
interest in such Person or the possession otherwise, directly or indirectly, of
the power to direct the management or policies of such Person.
1.2. "Agreement Product" shall mean hylan gel-fluid 20 (hylan G-F 20)
Synvisc(R) for the intra-articular treatment by viscosupplementation of
osteoarthritis of the knee, to be supplied in Syringes ready for use complying
with the Product Approvals and falling within the scope of the Patents (to the
extent Biomatrix has a Patent in the relevant country in the Territory) all as
further described in the Agreement Product Specifications, together with any
Improvements (as defined below) to the Agreement Product for such treatment.
1.3. "Agreement Product Specifications" shall mean the specifications
for the Agreement Product set forth in Exhibit A, as such specifications may be
modified from time to time to reflect Improvements as notified by Biomatrix to
the Distributor.
1.4. "Agreement Year" shall mean the twelve (12) month period
commencing on the first day of the first month following the Effective Date, and
each separate successive twelve (12) month period thereafter.
1.5. "Annual Effective Exchange Rate" shall mean, with respect to any
Applicable Currency, for the period commencing on the Effective Date and ending
on the last day of the first Agreement Year the daily average of the exchange
rate between such Applicable Currency and the US Dollar for the thirty (30) days
prior to the Effective Date as published in The Wall Street Journal (or, if The
Wall Street Journal shall no longer publish such exchange rates, as determined
by a method that is mutually agreed upon in writing by the parties). For each
Agreement Year thereafter, the Annual Effective Exchange Rate shall equal
*
The Average Exchange Rate for a twelve month period shall mean the daily average
of the exchange rate between such Applicable Currency and the US Dollar for such
period using the average month-end rates of exchange for the such period as
published in The Wall Street Journal (or if The Wall Street Journal shall no
longer publish such exchange rates, as determined by a method that is mutually
agreed upon in writing by the parties).
1.6. "Applicable Currency" shall mean, with respect to a country in the
Territory, the lawful currency of such country.
*Confidential portions have been omitted and filed separately with the
Commission
<PAGE> 3
1.7. "Committee" shall mean that term as defined in Section 8.9.
1.8. "Confidential Information" shall mean that term as defined in
Section 7.1(a).
1.9. "Contract Month" shall mean the period commencing with the first
day of the first Agreement Year and ending on the last day of the first complete
calendar month thereafter, and each one (1) calendar month period thereafter
throughout the term of this Agreement.
1.10. "Contract Quarter" shall mean the period commencing with the
first day of the first Agreement Year and ending on the last day of the first
complete calendar quarter thereafter, and each one (1) calendar quarter period
thereafter throughout the term of this Agreement.
1.11. "Effective Date" shall mean the date of this Agreement.
1.12. "Employment Costs" shall mean, with respect to any employee of
Biomatrix for any period, all costs related to such employee's hiring and
employment, such as base salary, bonuses earned or awarded, social security
costs, payroll or other taxes, and expense reimbursements, such costs to be
comparable to the costs of other similarly-situated employees employed in
France.
1.13. "Formula Price" shall mean that term as defined in Section
9.2(b).
1.14. "French Franc" and "FF" shall mean the lawful currency of the
Republic of France; provided, if the French Franc is replaced by a European
currency, references to "French Franc" and "FF" shall mean references to such
currency, and the amounts expressed herein in French Francs shall be converted
to such currency at the exchange rate fixed at the time of replacement by such
currency.
1.15. "Improvements" shall mean extensions of the label claims for the
Agreement Product, including new dosage and presentation forms
*
and packaging improvements for the Agreement Product.
1.16. "Initial Term" shall mean that term as defined in Section 3.1(a).
1.17. "Minimum Price" shall mean that term as defined in Section
9.2(b).
*Confidential portions have been omitted and filed separately with the
Commission
<PAGE> 4
1.18. "Minimum Sale Amount" shall mean that term as defined in Section
9.3(c).
1.19. "Net Revenues" shall mean, for a specified period, an amount
calculated in French Francs and equal to the total gross invoice price from the
sale of all Agreement Product by the Distributor and its Affiliates during such
period in the Territory to non-Affiliated wholesalers, hospitals, retail
pharmacies, patients and other third party purchasers, * for purposes of this
calculation (but for the avoidance of doubt this clause shall not prohibit * but
for the avoidance of doubt this clause shall not prohibit For avoidance of
doubt, sales of Agreement Product to Affiliates that will be resold shall not be
regarded as sales for the purposes of calculating Net Revenues. The amounts used
in the calculations of Net Revenues shall be determined from the books and
records of the Distributor (or its Affiliates, as applicable) maintained in
accordance with generally accepted accounting principles consistently applied.
1.20. "Patents" shall mean any Letters Patent or similar statutory
rights relating to the Agreement Product (including any continuation-in-part,
continuation or division thereof or substitute thereof), and patent applications
which are pending as of the Effective Date, in each
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 5
case as set forth on Exhibit B, together with any supplementary or complementary
protection certificates therefor if and when such are granted.
1.21. "Person" or "person" shall mean an individual, a corporation, a
partnership, a trust, an unincorporated organization or a government or any
agency or political subdivision thereof.
1.22. "Product Approvals" shall mean, for any country in the Territory,
those regulatory approvals required for importation, promotion, pricing,
marketing and sale of the Agreement Product in such country.
1.23. "Reimbursement Approvals" shall mean governmental and other
approvals in any country in the Territory for a buyer to claim reimbursement at
any level for the purchase of the Agreement Product from private or public
health insurance organizations in such country.
1.24. "Supply Forecast" shall mean that term as defined in Section
9.3(b).
1.25. "Syringe" shall mean a pre-packaged 2.0ml syringe of the
Agreement Product.
1.26. "Territory" shall mean the Republic of France, including DOM TOM
(as defined below), Algeria, Morocco and Tunisia. For the purpose of this
Agreement, "DOM TOM" shall mean French Guyana, Martinique, Reunion, Guadeloupe,
St. Pierre and Miquelon ("Departements d'Outre Mer" or "DOM"); and Mayotte,
Wallis and Futuna, New Caledonia and Dependencies and French Polynesia
("Territories d'Outre Mer" or "TOM").
1.27. "Trademarks" shall mean (i) the trademark Synvisc(R) which is
owned by Biomatrix and described on Exhibit B, and (ii) any other trademarks, as
may be agreed upon in writing from time to time by the parties hereto for use by
the Distributor in connection with the promotion, marketing and sale of the
Agreement Product under this Agreement.
1.28. "Treatment Pack" shall mean a quantity of the Agreement Product
sufficient for one treatment, consisting of three (3) Syringes.
1.29. "US Dollars" and "$" shall mean the lawful currency of the United
States of America.
<PAGE> 6
2. APPOINTMENT AND ACCEPTANCE OF DISTRIBUTORSHIP; CERTAIN PAYMENTS
2.1. APPOINTMENT.
(a) Subject to the terms and conditions hereinafter set forth,
Biomatrix hereby appoints the Distributor as its exclusive (except where
Biomatrix has the right to convert this Agreement to non-exclusive, such as in
Section 9.3(e)) distributor within the Territory for the promotion, marketing,
sale and distribution of the Agreement Product supplied by Biomatrix to the
Distributor pursuant to this Agreement.
(b) Except as specifically provided to the contrary herein, the
foregoing appointment shall not be construed (i) to effect any sale of
proprietary Biomatrix technology, (ii) to grant any license relating to
Biomatrix's technology, including its proprietary methods of formulating,
fabricating and manufacturing the Agreement Product, or (iii) to grant the
Distributor any rights in or to any proprietary technology or Patents or
Trademarks of Biomatrix by implication or otherwise. For the avoidance of doubt,
the limitations in this Section 2.1(b) shall not affect the exclusivity of the
appointment in Section 2.1(a) or the exclusivity of the supply obligation in
Section 9.1. Except as specifically authorized under this Agreement, the
Distributor has no authority to appoint any subagent, subdistributor or other
person to promote the sale of the Agreement Product or to otherwise perform any
of Distributor's obligations hereunder and agrees to refrain from using any such
subagents, subdistributors or other persons.
(c) During the term of this Agreement, unless otherwise agreed in
writing by Biomatrix, the Distributor shall neither seek customers for the
Agreement Product outside the Territory, nor establish any branch, subsidiary,
agent, or representative or maintain any distribution facilities outside the
Territory for the promotion, marketing, sale or distribution of the Agreement
Product or any similar product under a different brand.
2.2. ACCEPTANCE OF OBLIGATIONS.
The Distributor hereby accepts the appointment as exclusive (except
where Biomatrix has the right to convert this Agreement to non-exclusive, such
as in Section 9.3(e)) distributor within the Territory for the promotion,
marketing, sale and distribution of the Agreement Product. The Distributor
hereby agrees to commence the marketing and selling of the Agreement Product in
the Territory (other than in Algeria, Morocco and Tunisia) before the end of
1996, subject to
<PAGE> 7
delays caused by regulatory authorities and to adequate supply of Agreement
Product for resale in the Territory ordered in accordance with the terms hereof.
*
2.3. INITIAL PAYMENTS.
On the Effective Date the Distributor shall pay to Biomatrix the amount
of
*
as an initial payment in partial consideration for the appointment of the
Distributor as exclusive (except where Biomatrix has the right to convert this
Agreement to non-exclusive, such as in Section 9.3(e)) distributor hereunder.
Such initial payment shall be non-refundable.
2.4. MILESTONE PAYMENTS.
In further consideration for its appointment as exclusive (except where
Biomatrix has the right to convert this Agreement to non-exclusive, such as in
Section 9.3(e)) distributor hereunder, the Distributor hereby agrees to make the
following additional non-refundable milestone payments:
(a) Payments on Decision to Continue Marketing with Reimbursement
Approval. From and after receipt of Reimbursement Approval in France, so long as
the Agreement is not terminated pursuant to Section 3.5, the Distributor shall
make the following payments, reduced by any payments previously made by the
Distributor under Section 2.4(b).
(i) A payment to Biomatrix of
*
so long as the Distributor has received Reimbursement Approval and has not
terminated the Agreement in accordance with Section 3.5.
(ii) A payment to Biomatrix of
*
*Confidential portions have been omitted and filed with separately with the
Commission.
<PAGE> 8
showing that the Distributor's cumulative Net Revenues (as defined below) since
the Effective Date exceed * .
(iii) A payment to Biomatrix of
* which the Distributor is required to deliver the
monthly report described in Section 9.2(e) for the last
Contract Month of the
* For the avoidance of doubt, the sales of Agreement
Product resulting in payment required by clause (ii) above
shall count towards the amount triggering the payment in this
clause (iii) if such sales are made during the first * period
* resulting in an aggregate milestone payment of * .
(b) Payments prior to reimbursement approval. Prior to receipt of
Reimbursement Approval in France, so long as the Agreement is not terminated
pursuant to Section 3.5, the Distributor shall make the following payments:
(i) A payment to Biomatrix of * which the Distributor is
required to deliver the monthly report described in Section 9.2(e) for
the last Contract Month of the * .
(ii) A payment to Biomatrix of * which the Distributor is
required to deliver the monthly report described in Section 9.2(e) for
the last Contract Month of the * For the avoidance doubt, the sales of
Agreement Product resulting in the payment required by clause (i) above
shall count towards the amount triggering the payment in this clause
(ii) if such sales are made during the * in which * , resulting in an
aggregate milestone payment of * .
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 9
(iii) A payment to Biomatrix of * which the Distributor is
required to deliver the monthly report described in Section 9.2(e) for
the last Contract Month of the * . For the avoidance of doubt, the
sales of Agreement Product resulting in the payments required by
clauses (i) and/or (ii) above shall count towards the amount triggering
the payment in this clause (iii) if such sales are made during the *
period * resulting in an aggregate milestone payment of *.
(c) Maximum Milestone Payments. For the avoidance of doubt, the maximum
amount payable under Section 2.4(a) shall not exceed * and the maximum amount
payable under Section 2.4(b) shall not exceed *.
2.5. NATURE OF PAYMENTS.
Each of the payments referred to in Sections 2.3 and 2.4 hereof are
independent of each other payment hereunder and shall not be deemed satisfied by
the making of any other payment hereunder (except to the extent payments under
2.4(b) are netted against payments made under 2.4(a)). All payments to be made
pursuant to Sections 2.3 and 2.4 shall be made in US Dollars.
2.6. OPERATIONS AND EXPENSES.
Except as otherwise set forth in this Agreement, the operations of the
Distributor under this Agreement are subject to the sole control and management
of the Distributor. The Distributor shall be responsible for all of its own
expenses and employees. The Distributor agrees that it shall incur no expense
chargeable to Biomatrix, except as may be specifically authorized in advance in
writing in each case by Biomatrix.
2.7. INDEPENDENT PARTIES.
Neither party shall be considered an agent or legal representative of
the other for any purpose (except to the limited extent provided in Section
15.1(a)), and neither party nor any director, officer, agent or employee of
either party shall be, or be considered, an agent or employee of the other
party. Neither party shall have or exercise the right or authority to assume
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 10
or create any obligation or responsibility, including without limitation
contractual obligations and obligations based on warranties or guarantees, on
behalf of or in the name of the other party.
3. TERM AND TERMINATION
3.1. TERM.
(a) Term. Unless this Agreement is sooner terminated in accordance with
the provisions of this Agreement, the term of the appointment hereunder shall
commence on the Effective Date and shall end on the last day of the * Agreement
Year (the "Initial Term"); provided, that the Initial Term shall be * if
Reimbursement Approval in France is obtained prior to the * of the Effective
Date. Following the Initial Term * shall have the right to * duration as to
which the parties may agree; provided that the conditions described in * below
have been satisfied; and provided further that the parties have mutually agreed
on the other terms and conditions for such renewal.
(b) Conditions to renewal. The renewal of the appointment in the
Territory shall take effect only if as of the date of expiration of the Initial
Term (i) the Distributor is not in material breach of any of its obligations
under this Agreement (including without limitation its obligations to make * of
the Agreement Product as set forth in Section 9.3), and (ii) the parties shall
have negotiated in good faith reasonable additional * Amounts and * for such
additional term. The * Amounts and * shall reflect market conditions such as
changes to the sales price to third parties, changes in the competitive
situation and other market factors.
3.2. *
(a) * Upon termination of this Agreement for * of the Agreement
Product * shall remain at the facilities of * for a period not to exceed *
(b) * of this Agreement * or upon a * Biomatrix shall have the *
by Biomatrix within * after such * of the Agreement Product * provided that
such *
(c) * for reasons other than * under Section 3.2(a)(i) or
3.2(b), * in accordance with the terms hereof during a period of * from the *
Thereafter, * of the Agreement Product that * in accordance with the provisions
of Section 3.2(a) *
3.3. INSOLVENCY.
This Agreement may be immediately terminated as to the entire Territory
by either party, upon giving written notice to the other party, in the event
that the other party (or any of its Affiliates in the Territory) shall become
insolvent or be declared bankrupt by a court of competent jurisdiction or shall
be the subject of any winding up, receivership or dissolution, bankruptcy,
administration or liquidation proceeding, or creditor's meeting, or any
proceeding or action similar to one or more of the above, in which case
termination shall be effective upon such written notice. The failure of either
party to give notice of termination upon obtaining knowledge of any such event
shall not be interpreted as a waiver of such party's rights under this Section
3.3, and such party reserves the right to exercise any such rights at any time
after the occurrence of any such event.
3.4. BREACH.
This Agreement may be terminated as to the entire Territory by a party
if the other party should breach any of its payment obligations hereunder or
should commit a material breach of
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 11
any of its warranties, covenants, conditions, obligations or agreements
contained herein; provided that in the case of a payment breach such breach
shall continue for a period of ten (10) business days after written notice
thereof and in the case of any other breach such breach shall continue for a
period of thirty (30) days after written notice thereof; and provided further
that such termination shall be immediately effective upon further written notice
to that effect to the breaching party after its failure to cure such breach
within such applicable notice period.
3.5. *
If the Distributor's price for sales of the Agreement Product direct to
patients resulting from Reimbursement Approval in France is * (without tax) per
Treatment Pack, * per Syringe, or if after using commercially reasonable efforts
the Distributor * the Distributor shall have the right, exercisable by written
notice to Biomatrix only during the Decision Period (as defined below), to
determine to continue with its rights and obligations under this Agreement, or
to notify Biomatrix that it desires to review the Minimum Price and the Minimum
Sale Amounts. For purposes of this Section 3.5, the "Decision Periods" shall be
* in France, or following the * as applicable. If Biomatrix receives no written
notice under this Section 3.5 during the Decision Period, then the Distributor
will be deemed to have determined to * under this Agreement in accordance with
the terms hereof. If Biomatrix receives a written request within the Decision
Period to review such matters, Biomatrix agrees to discuss * and any other terms
and conditions of this Agreement in an attempt to * in accordance with the
process described in Section 8.13 (a) and (b).
3.6. CERTAIN RIGHTS UPON TERMINATION.
(a) Access to data. Upon any termination of this Agreement for any
reason, to the extent not prohibited by applicable law, Biomatrix shall have the
right to review, access, use and permit others to review, access and use, either
directly or by cross-reference or incorporation or otherwise, all information,
data, investigations, preclinical and clinical protocols (including without
limitation marketing information and information relating to clinical studies),
and related regulatory approvals pertaining to the Agreement Product (the
"Information") which are possessed or controlled by the Distributor or any of
its Affiliates, or to which the Distributor or
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 12
any of its Affiliates has a right to review, access or use. The Distributor
unconditionally agrees promptly to take any action and to execute and deliver to
Biomatrix any documents or instruments reasonably requested by Biomatrix to
permit Biomatrix to make full use of such right.
(b) Ownership of Trademarks. Biomatrix shall have exclusive ownership
rights to the Trademarks and to all other product specific logos, slogans and
other intangibles used by the Distributor (and which are not owned by any third
party) in connection with the Agreement Product (including all registrations
relating thereto). The Distributor shall notify Biomatrix prior to the use of
any product specific logos, slogans and other intangible assets (other than the
Trademarks), and shall cooperate with Biomatrix if Biomatrix determines to
register its rights in such logos, slogans and other intangible assets (to the
extent Biomatrix has rights in such logos, slogans and other intangible assets).
The Distributor shall not apply for the registration of any Trademarks, and no
Trademarks or any trademarks similar to the Trademarks shall be in the name of
or otherwise held or owned by the Distributor.
(c) Termination of Right to Use Trademarks. Subject to the right to
sell out its stock in accordance with Section 3.2(b), the Distributor
unconditionally agrees, upon any termination of this Agreement, (i) immediately
to cease using the Trademarks and any logos and slogans relating to the
Agreement Product and (ii) immediately to execute and deliver to Biomatrix at
the Distributor's own expense any documents or instruments reasonably requested
by Biomatrix to give full effect to the provisions of this Section 3.6.
(d) Transfer of price and reimbursement approvals. Subject to the right
to sell out its stock in accordance with Section 3.2(b), the Distributor
unconditionally agrees that upon any termination of this Agreement it shall,
upon the request of Biomatrix, immediately inform all relevant regulatory
authorities that the Distributor is no longer a distributor of the Agreement
Product and, to the extent not prohibited by applicable law, shall take all
action and execute and deliver all documents and instruments necessary in order
to transfer at the Distributor's own expense all Product Approvals and
Reimbursement Approvals and other relevant documents relating to the Agreement
Product in favor of Biomatrix or any Person designated by Biomatrix; provided,
that if Biomatrix requests the Distributor to take such actions for any reason
other than a breach by the Distributor or a termination by Biomatrix pursuant to
Section 8.13(b), Biomatrix shall reimburse the Distributor for any actual out of
pocket costs incurred at the request of Biomatrix in connection with such
transfers.
<PAGE> 13
3.7. EFFECTS OF TERMINATION.
(a) Upon termination of this Agreement for any reason and after the
sell-out period set forth in Section 3.2(b) has expired, the Distributor shall
immediately discontinue making any representation regarding its status as a
distributor for Biomatrix in the Territory or the applicable portion thereof and
shall immediately cease conducting any activities with respect to the marketing,
promotion, sale or distribution of the Agreement Product in the Territory.
(b) Termination of this Agreement shall not affect obligations of
either party that may have accrued prior to the effective date of termination or
any obligation specifically stated to survive termination. Except to the extent
limited by Section 3.8, termination of this Agreement shall be in addition to,
and shall not be exclusive of or prejudicial to, any other grounds for
termination or rights or remedies at law or in equity which either party may
have on account of any default of the other party.
3.8 WAIVER.
The Distributor and Biomatrix hereby waive, to the extent they are able
to do so under applicable law, any statutory rights they may have or acquire
under the laws of any country in the Territory in respect of the termination of
the relationship established hereby pursuant to the terms hereof, and agree that
the rights available to them hereunder in the event of such termination are
adequate and reflect the agreement of the parties. Neither the Distributor, nor
Biomatrix nor any of their respective Affiliates shall have any right to claim
any indemnity for goodwill or lost profits or any damages arising from the
rightful termination of this Agreement by the other party in accordance with the
terms hereof (including a rightful termination under Section 8.13(b)).
4. PAYMENTS; EXCHANGE RATE
4.1. WIRE TRANSFER.
All payments hereunder shall be made in US Dollars. Payments to
Biomatrix by or on behalf of the Distributor shall be wired to an account in a
bank designated by Biomatrix and the costs of any such remittance shall be borne
by the Distributor.
<PAGE> 14
4.2. CONVERSION OF NON-US CURRENCY.
(a) For purposes of the calculation of the Formula Price, Net Revenues
denominated in an Applicable Currency shall be converted into US Dollars at the
Annual Effective Exchange Rate then in effect.
(b) For any other purpose hereunder, amounts denominated in an
Applicable Currency shall be converted to US Dollars at the average daily
exchange rate between the US Dollar and the Applicable Currency for the Contract
Month or other applicable period, as published in The Wall Street Journal (or
another mutually acceptable publication).
5. WITHHOLDING
All payments to be made by the Distributor under this Agreement shall
be made in full, free and clear of and without any deduction of or withholding
for or on account of any taxes levied in any country of the Territory or
elsewhere; provided that if the Distributor shall be required by law to make any
deduction or withholding from any payment to Biomatrix then:
(i) the Distributor shall ensure that such deduction or withholding
does not exceed the minimum legal liability therefor;
(ii) as soon as possible prior to the first deduction or withholding,
the Distributor shall notify Biomatrix thereof, and the parties shall negotiate
in good faith adjustments to the payments hereunder in order to minimize or
eliminate such deduction or withholding;
(iii) the Distributor shall forward to Biomatrix such documentary
evidence as may be requested by Biomatrix in respect of each deduction,
withholding or payment together with each payment or promptly thereafter; and
(iv) if the parties cannot adjust the payments hereunder to eliminate
all deductions and withholding, the parties shall attempt in good faith to agree
upon revised mutually acceptable pricing and/or payment terms.
6. COMPETING PRODUCTS
6.1. NON-COMPETITION BY THE DISTRIBUTOR.
In recognition of the rights granted by Biomatrix to the Distributor
and the other obligations of Biomatrix hereunder, the Distributor agrees that it
shall not, directly or indirectly (alone
<PAGE> 15
or with others), and it shall ensure that its Affiliates shall not, directly or
indirectly (alone or with others), during the period commencing on the Effective
Date and continuing for the term of this Agreement, promote, manufacture, sell,
market or distribute a Competing Product anywhere in the Territory. "Competing
Product" shall mean any product for the treatment of osteoarthritis or
rheumatoid arthritis using any substances applied intra-articularly for the
alleviation of pain and/or improvement of joint function by
viscosupplementation. The Distributor acknowledges and agrees that in the event
of a breach or threatened breach by the Distributor of its obligations under
this Section 6.1, Biomatrix will have no adequate remedy at law, and accordingly
shall be entitled to injunctive or other appropriate equitable remedies with
respect to such breach or threatened breach in addition to any other remedies
which Biomatrix may have.
6.2. *
During the term of this Agreement, Biomatrix * Biomatrix or its
Affiliates for * Each * shall, if * governed by the terms and conditions of this
Agreement; provided, however, that such * terms and conditions of this Agreement
* as Biomatrix may determine in * The parties will * terms and conditions
applicable to the * and will take into account the * at such time, including the
* of the Agreement Product (including with respect to * and the * If the parties
* provided, that the aggregate of any * of the aggregate amount of * and that
the other terms and conditions of the agreement * If Biomatrix enters into a *
and any negotiations shall be conducted in accordance with the process set out
in Section 8.13(a), and if the parties cannot agree the *
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 16
7. CONFIDENTIAL INFORMATION; PUBLIC ANNOUNCEMENTS
7.1. CONFIDENTIAL INFORMATION.
(a) All information acquired by either party (the "Recipient") from the
other party or any of its Affiliates (the "Discloser") during the term of this
Agreement or prior to the Effective Date, relating directly or indirectly to the
present or potential business, operations, corporate, technical or financial
situation of the Discloser, or to manufacturing know-how, patents, data, test
results, techniques, processes, procedures, raw materials, dealer, supplier and
customer lists or the Information described in Section 3.6 (collectively, the
"Confidential Information") is confidential.
(b) Unless otherwise agreed to in writing by the Discloser, the
Recipient shall not at any time, either during or for a period of five (5) years
subsequent to the term of this Agreement, use for itself (other than in
accordance with the terms of this Agreement) or any other Person, or disclose or
divulge to any Person, other than to those of its employees and advisors and
Affiliates who require the same for the purposes hereof and who are bound by the
same obligations of confidentiality, non-disclosure and non-use as set forth
herein, any Confidential Information or any other confidential or proprietary
information of the Discloser of which the Recipient may acquire knowledge;
provided, however, that the confidentiality, non-disclosure and non-use
provisions contained in this Section 7.1 shall not apply to any information or
data to the extent that the Recipient:
(i) shall demonstrate by written evidence that such
information or data is known generally to persons in the trade through no act or
omission of the Recipient or any of its Affiliates;
<PAGE> 17
(ii) is required by any government authority to disclose such
information or data, and/or for the purposes of obtaining and maintaining any
Product Approvals under this Agreement; or
(iii) shall demonstrate by its written records that such
information or data was disclosed to it or its Affiliates on a non-confidential
basis from a source other than the Discloser or its Affiliates and that such
disclosure did not constitute a breach of any applicable confidentiality
obligations.
Upon the reasonable request of the Discloser, the Confidential Information that
has been clearly marked "confidential" and that is specified in any such request
shall be immediately returned to the Discloser upon termination of this
Agreement, along with any copies, reproductions, digests, abstracts or the like
of all or any part thereof in the Recipient's possession or under the
Recipient's control, and upon such return any computer entries or the like
relating thereto shall, to the extent legally permissible, be destroyed. The
Recipient shall then attest to the Discloser in writing as to the return and/or
destruction of the Confidential Information. Such return (and destruction) will
not affect the Recipient's obligations hereunder which shall survive until five
(5) years after termination of this Agreement. Notwithstanding anything herein
to the contrary, the provisions of this Section 7.1 shall be subject to
Biomatrix's rights under Section 3.6.
Each party agrees to ensure that each of its Affiliates takes whatever
corporate action may be required to carry out its obligations under this Section
7.1.
7.2. PUBLIC ANNOUNCEMENT.
Except as is necessary for governmental notification purposes or to
comply with applicable laws and regulations or to enforce their respective
rights under this Agreement, and except as otherwise agreed to by the parties
hereto in writing, (i) the parties agree to keep the material terms of this
Agreement strictly confidential, (ii) the parties shall agree upon the text and
the exact timing of an initial public announcement relating to the transactions
contemplated by this Agreement as soon as possible after the Effective Date and
(iii) the parties shall agree on the text and the exact timing of any subsequent
public announcements regarding this Agreement or the transactions contemplated
herein.
<PAGE> 18
8. TRADEMARKS; AGREEMENT PRODUCT MARKING; PROMOTIONAL INFORMATION
8.1. TRADEMARKS.
Biomatrix hereby licenses to the Distributor the right to use, and
hereby requires the use of, the Trademarks in connection with the promotion,
marketing and sale of the Agreement Product in the Territory during the term of
this Agreement. Such license shall be free of charge, but shall remain in force
only to the extent provided in Section 8.2. The Distributor agrees that it shall
not use any of the Trademarks at any time outside the Territory or use any of
the Trademarks for any products other than the Agreement Product within the
Territory, or for any other purpose except as provided herein. The parties shall
execute a short form Trademark license agreement to the extent that it is
necessary to record the Trademark license hereunder in any country whose laws
require such recordation. Biomatrix shall take such actions as are reasonably
required to maintain the Trademarks in effect, and shall inform the Distributor
of any changes in or additions to the Trademarks.
8.2. TERMINATION OF RIGHT TO USE TRADEMARKS.
Subject to the sell-out right set forth in Section 3.2(b), upon
termination of this Agreement, the license to the Distributor to use the
Trademarks in the Territory shall terminate, and the Distributor unconditionally
agrees promptly to take all necessary action and execute and deliver to
Biomatrix all necessary documents and instruments to remove the Distributor as a
registered user and/or a recorded licensee of the Trademarks.
8.3. NOTICE OF INFRINGEMENT.
Each party hereto agrees to notify the other in writing promptly (but
not later than thirty (30) days) after obtaining knowledge of any infringements
or imitations of the Trademarks by third parties. Further, the Distributor
agrees to notify Biomatrix immediately after it becomes aware that any Agreement
Product sold in the Territory is thereafter sold or transported outside the
Territory.
<PAGE> 19
8.4. MARKETING AND PROMOTIONAL PLANS AND MATERIALS.
(a) Preliminary Promotional Plan and Budget. The parties have attached
as Exhibit E hereto two versions of a preliminary promotional plan and budget,
one showing the amount and timing of planned promotional expenditures for the
Agreement Product in the Territory assuming receipt of Reimbursement Approval in
France, and the other version showing such expenditures assuming no such
Reimbursement Approval. These preliminary promotional plans and budgets
represent the general level of investment that the Distributor will include in
the plan described in paragraph (b) below, and the Distributor will use
commercially reasonable efforts to implement the general level of investment of
such plans and budgets in good faith in connection with the marketing and sale
of the Agreement Product in the Territory.
(b) Marketing and Sales Plan. The Distributor, in good faith and in
cooperation with Biomatrix, shall prepare and provide to Biomatrix, promptly
following the Effective Date but before January 31, 1997, and annually by the
end of the third quarter of each year, a marketing, promotional, sales and field
force deployment plan and budget (including a description of the job
responsibilities for each Product Specialist, a * sales forecast and a * supply
forecast) describing the marketing and sales of the Agreement Product to
relevant customer groups (such as doctors, patients and hospitals) in the
Territory through appropriate means. The Distributor shall provide copies of all
such plans and changes to or updates of such plans and schedules to Biomatrix at
least two weeks prior to the Committee meeting to review such plans. Such
initial plans shall be reviewed by the Committee before February 14, 1997. The
annual plan for each year shall be reviewed by the Committee at the annual
meeting in September. Any major changes to or updates of such plans or schedules
shall be reviewed by the Committee at the request of either party.
8.5. LEGEND.
Subject to applicable laws and regulations in the Territory, all
relevant packaging and promotional material for the Agreement Product used or
sold by the Distributor shall contain (i) all applicable markings needed to keep
the Trademarks enforceable throughout the Territory as specified in writing by
Biomatrix to the Distributor, and (ii) a legend substantially in the form
attached as Exhibit C, which shall be displayed in a reasonably conspicuous
manner on all packaging of such Agreement Product containing the corporate
identification logo of Biomatrix and indicating that such product has been
developed and manufactured by Biomatrix, Inc., and its affiliates, 65 Railroad
Avenue, Ridgefield, New Jersey, 07657 U.S.A. or similar statement
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 20
such as is consistent with Biomatrix's practice in distributing the Agreement
Product in other territories and which shall also contain the information
supplied by the Distributor and set forth on Exhibit C. Biomatrix and the
Distributor shall each have the right to modify the information provided by it
for such legend from time to time, and the other party shall have the right to
consent to each such modification, such consent not to be unreasonably withheld.
8.6. LABELLING AND PROMOTION MATERIALS; APPROVED USE OF PRODUCTS.
(a) The Distributor shall provide Biomatrix with labelling masters,
instructions, specifications and copies of all marketing, labelling and
promotional material it intends to use relating to the Agreement Product and any
Improvements. All such labelling, packaging and promotional material shall be
consistent with the relevant Product Approvals and all labelling, packaging and
promotional materials shall be reviewed by Biomatrix and shall be subject to its
written approval prior to use, such approval not to be unreasonably withheld,
and such approval or disapproval to be communicated to the Distributor within *
after its receipt of such materials; provided, that if such materials impact any
Regulatory Approvals within or outside the Territory, Biomatrix shall not be
obligated to communicate its approval or disapproval until it is satisfied that
all Regulatory Approvals have been obtained and will not be adversely affected
by the use of such materials. Such review shall be limited to scientific,
medical and international product positioning matters. The Distributor shall
provide Biomatrix with all major promotional materials for launches and
subsequent promotions within a reasonable time prior to their use in order to
allow Biomatrix to comment on such materials. The Distributor shall provide
Biomatrix with copies of all other promotional materials at or prior to their
use. This Section 8.6(a) shall not limit Biomatrix's right to control usage of
the Trademarks, as provided in the other provisions of this Agreement.
(b) The Distributor agrees that its promotion, marketing, sale and
distribution of the Agreement Product and any Improvements in the Territory, and
the promotional materials and labelling used in connection therewith, shall be
strictly in accordance with the approved use of the Agreement Product and any
Improvements as specified in the Product Approvals and as further provided in
this Agreement.
8.7. PROMOTIONAL SUPPORT.
(a) Samples. In each of the first three Agreement Years Biomatrix shall
provide the Distributor, upon its request in accordance with the provisions of
Section 9.4(b), with
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 21
promotional support by supplying to the Distributor not more than the number of
Syringes set forth on Exhibit D for each such Agreement Year to be used by the
Distributor in implementation of the marketing and sales plan. The Distributor
hereby agrees to pay Biomatrix * for each such Syringe.
(b) Exchange of information. Biomatrix and the Distributor shall
provide to each other on an ongoing basis and without charge (to the extent not
prevented by law or contract from doing so) all marketing, medical, scientific,
technical and other information relating to the Agreement Product (including
summary data from studies, clinical trials, competitive products and the like as
well as information regarding adverse events associated with the use of the
Agreement Product) that is available to such party upon the reasonable request
of the other party. In addition, Biomatrix and the Distributor shall provide
each other with access to such primary data and information in its possession as
the other may reasonably request regarding the results of the studies contained
in such summary data referred to above.
(c) Reference to viscosupplementation and Biomatrix. Subject to
applicable laws and regulations in the Territory, and without risk of liability
to the Distributor, the Distributor shall ensure that all trade literature,
publications and promotional materials relating to the Agreement Product
produced by or on behalf of the Distributor or any of its Affiliates shall
specify the concept of viscosupplementation as conceived and introduced by
Biomatrix and as defined by Biomatrix in the trade literature.
8.8. [RESERVED].
8.9. JOINT COMMITTEE.
The parties shall establish a joint committee (the "Committee")
comprised of from two (2) to four (4) voting representatives designated by each
of the parties, with an equal number appointed by each of the parties. The
Distributor and Biomatrix shall each appoint one of its voting representatives
to act as a co-chairman of the Committee. The Committee will meet annually (at
the end of September) or more frequently if requested by either party. The
Committee shall have responsibility to review business, marketing, scientific
and medical issues, and such other matters referred to them by the parties'
respective operational teams having internal responsibility for the Agreement
Product, in accordance with the provisions of Section 8.13(a).
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 22
8.10. PRODUCT VIGILANCE SYSTEM.
The Distributor shall be responsible for maintaining medical device
vigilance systems in each country in the Territory, as established for the
Agreement Product by Biomatrix in accordance with local regulations, and shall
promptly provide Biomatrix with notice of all product complaints, including
medical complaints. Biomatrix shall be solely responsible for processing the
final analysis of medical complaints. The Distributor shall provide all
necessary support to Biomatrix for carrying out such activities. If required by
local regulations, the Distributor is responsible for reporting medical
complaints to the local authority; provided that the Distributor shall consult
with Biomatrix in each case prior to making such report and Biomatrix and the
Distributor will cooperate to promptly report the medical complaint to the local
authority. Biomatrix shall promptly provide the Distributor with notice of all
serious foreign product complaints.
8.11. PRODUCT SPECIALISTS.
Promptly following the Effective Date, Biomatrix shall provide
assistance with the marketing and sale of the Agreement Product in the Territory
by making available * Biomatrix employees to work with the Distributor's sales
force. Prior to the end of the * Agreement Year, the parties shall discuss
additional assistance by Biomatrix for the * Agreement Years. Notwithstanding
the foregoing, at any time after the parties have received Reimbursement
Approval Biomatrix shall have the right to provide the assistance through up to
* employees to work with the Distributors sales force. Such Biomatrix employees
(the "Product Specialists") shall be hired, trained and managed by Biomatrix at
the Distributor's expense (subject to the limits provided below), and their job
responsibilities will be included in the marketing plan prepared and approved in
accordance with Section 8.4. Biomatrix shall assist the Distributor's marketing
and sales force in accordance with the marketing plans prepared as provided in
Section 8.4, provided that (i) all sales of the Agreement Product in the
Territory by the Product Specialists shall be made * of the Agreement Product
in the Territory pursuant to Section 9.3(e) * (ii) * in consideration for such
assistance, the Distributor shall pay * with respect to each of the Product
Specialists, * for each Product Specialist * (iii) * in consideration for such
assistance, the Distributor shall pay * with respect to each Product Specialist
* (iv) * with respect to each Product Specialist * for approximately * and (v)
* Year Biomatrix shall have the right to require that the Product Specialists *
during the working hours * the Agreement Product, subject to any agreement
entered into by the parties after the Effective Date pursuant to *
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 23
Other than the Employment Costs for which the Distributor is responsible
pursuant to this Section 8.11 and subject to the provisions of Section 10.3,
Biomatrix shall be responsible for the actions and omissions of the Product
Specialists while employed by Biomatrix so long as they are acting within the
scope of their employment.
8.12. RECALLS OF THE AGREEMENT PRODUCT.
(a) If the * in a country in the Territory * of the Agreement
Product, the Distributor and Biomatrix shall * in such country, and shall
cooperate to *
(b) Subject to Section 8.12(a) above, if either party *
such party shall * and shall advise such other party of the * The parties shall
consult with each other * but in any event if after consultations *
(c) Except as otherwise provided in (d) below, in the event of a
recall of the Agreement Product, Biomatrix shall correct any deficiency
relating to its manufacturing, packaging, testing, labelling, storing or
handling of the Agreement Product for which it is responsible, if applicable,
and shall at its cost replace the Agreement Product recalled.
(d) Biomatrix shall reimburse the Distributor for all direct costs
and expenses (including without limitation shipping, quality control testing
and notification costs) incurred by the Distributor as a result of any recall,
except where such recall (i) is the result of the failure of the Distributor to
comply with its obligations under this Agreement and/or (ii) was opposed by
Biomatrix and proved to be unwarranted, in which case the Distributor shall
reimburse Biomatrix for all direct costs and expenses (including without
limitation shipping, quality control testing and notification costs) incurred
by Biomatrix as a result of such recall.
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 24
8.13. DISPUTE RESOLUTION PROCESS.
(a) All decisions which by the terms of this Agreement are to be made
mutually by the Distributor and Biomatrix shall be made in accordance with this
Section 8.13. Initially all such decisions are to be made after mutual
consultation by the operational teams at each of the Distributor and Biomatrix
having internal responsibility for the Agreement Product and its distribution in
the Territory. If the parties are unable to make any such decision at the
operational level, then the Committee will review the matter at its next meeting
and attempt to make a mutually acceptable decision. If the Committee is unable
to make such decision, the parties agree to submit the matter to their
respective chief executive officers, who shall attempt to resolve the matter as
soon as possible.
(b) If the chief executive officers cannot resolve the matter within a
reasonable period of time, either party shall have the right, by written notice
to the other party, to terminate this Agreement at any time after the expiration
of six months following such notice or at such other time as the chief executive
officers of the parties may agree.
8.14. QUESTIONABLE PAYMENTS.
Neither the Distributor nor Biomatrix shall, directly or indirectly, in
the name of, on behalf of, or for the benefit of the other party hereto offer,
promise, authorize to pay, or pay any compensation or give anything of value to,
any official, agent or employee of any government or governmental agency or to
any political party or officer, employee or agent thereof.
<PAGE> 25
9. SUPPLY OF AGREEMENT PRODUCT
9.1. GENERAL.
Biomatrix agrees to sell the Agreement Product to the Distributor, on
the terms and subject to the conditions set forth herein, on an exclusive basis
(except where Biomatrix has the right to convert this Agreement to
non-exclusive, such as in Section 9.3(e)) for resale by the Distributor within
the Territory, and the Distributor shall obtain the Agreement Product for resale
in the Territory only from Biomatrix. As used in this Section 9.1, the term
"exclusive" shall mean that, to the extent permitted by applicable law
(including without limitation EU competition law), Biomatrix shall not supply
the Agreement Product into the Territory, or authorize any third party to
solicit orders for the Agreement Product in the Territory, except where
Biomatrix has the right to convert this Agreement to non-exclusive, such as in
Section 9.3(e).
9.2. PRICE AND QUANTITY.
(a) Supply price. During the * Agreement Years, the price payable by
the Distributor to Biomatrix shall be * per Syringe. From the * Agreement Year
to the * of this Agreement, the price payable by the Distributor to Biomatrix
shall be *
(b) Minimum Price and Formula Price.
(i) The "Minimum Price" shall be * per Syringe; provided that
beginning with the * for the immediately preceding calendar year * . In the
event that there shall arise any * then the parties shall *
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 26
(ii) The "Formula Price" for each of the first * Syringes sold
in the Territory during an Agreement Year shall equal * for such Syringes,
divided by the number of Syringes sold up to * , and for each Syringe sold over
* in the Territory during an Agreement Year shall equal * for such Syringes,
divided by the number of Syringes sold in excess of *.
(c) Adjustments based on Formula Price. Beginning with the first
Contract Quarter of the third Agreement Year, and for each succeeding Contract
Quarter, the price initially payable by the Distributor for sales of the
Agreement Product in such quarter shall be * for the immediately preceding
Contract Quarter, and within * of each Contract Quarter, the Formula Price for
sales of the Agreement Product in such Contract Quarter shall be calculated in
accordance with * and, to the extent that such * exceeds the price paid for
sales in such Contract Quarter, an adjustment resulting from the difference
between such prices shall be paid by the Distributor within * following the end
of such Contract Quarter. For the avoidance of doubt, the amount resulting from
each adjustment shall be paid within * referred to above and the aggregate
amount payable by the Distributor for the Agreement Product for any Agreement
Year shall in any event not be lower than the *
(d) Currency and Timing of payments. All purchases of the Agreement
Product hereunder shall be billed to and paid by the Distributor in US Dollars
within * after the later of (i) the date of invoice for such shipment or (ii)
the date of delivery to the port of entry in the Territory. All payments to be
made as a result of the adjustments set forth in this Section 9.2 shall be made
in US Dollars. Net Revenues denominated in an Applicable Currency used for the
calculation of such payments shall be converted to US Dollars at the exchange
rates set forth in Section 4.2(a).
(e) Monthly reports. Within * following the end of each Contract Month
(or such other period as may be agreed by the parties) in each Agreement Year
for each country in the Territory, the Distributor shall submit to Biomatrix
written reports detailing the units and value of the Distributor's and its
Affiliates' sales of the Agreement Product in each country during the
immediately preceding calendar month (or such other agreed period).
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 27
(f) Yearly reports. Within * following the end of each Agreement Year
for each country in the Territory, the Distributor shall submit to Biomatrix
written reports detailing the Distributor's and its Affiliates' sales of the
Agreement Product in each country during the immediately preceding Agreement
Year, which reports shall contain the Net Revenues of the Agreement Product for
each country in the Territory from sales during the applicable year to third
party purchasers who are not Affiliates of the Distributor, and the aggregate
number of units of the Agreement Product sold in each country in the Territory
during the applicable Agreement Year.
(g) Obligation to supply. Biomatrix and its Affiliates shall use
commercially reasonable efforts to sell the Agreement Product to the Distributor
in such quantities and at such times as the Distributor may, pursuant to the
provisions hereof, order from time to time; provided that Biomatrix and its
Affiliates shall not be in breach of this Agreement if (i) they fail to supply
the Distributor with quantities of the Agreement Product in any Contract Quarter
in excess of * of the amount in the Supply Forecast for such Contract Quarter
delivered to Biomatrix * prior to such Contract Quarter or (ii) they shall be
subject to a force majeure event, as defined in Section 20.
(h) Failure to supply. If Biomatrix is unable to supply the Agreement
Product ordered by the Distributor in accordance with the terms of this
Agreement, then Biomatrix shall use commercially reasonable efforts to remedy
the problem or secure an alternative source of supply within a reasonable time
at no cost to the Distributor, and any such alternative source of supply shall
be on terms substantially identical with the terms of this Agreement. Each of
the parties shall cooperate with the other to secure an alternative source of
supply if Biomatrix is unable to supply the Agreement Product itself. If
Biomatrix is unable to remedy the problem or secure an alternative source of
supply within three (3) months after its initial failure to supply, then
Biomatrix shall consult with the Distributor and the parties shall work
together at Biomatrix's premises to remedy the problem. If Biomatrix is unable
to remedy the problem after an aggregate period of six (6) months (or longer as
agreed in writing by the parties), commencing with the date upon which such
failure to supply began, then the Distributor may at its option terminate this
Agreement.
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 28
9.3. SALES AND SUPPLY FORECASTS; MINIMUM SALES.
(a) Sales Forecasts. Exhibit D attached hereto sets forth sales
forecasts for sales of units of the Agreement Product in the Territory for each
of the * Agreement Years. Within * after the expiration of the * Agreement Year
and within * after the expiration of * Agreement Year thereafter, the
Distributor shall provide to Biomatrix a sales forecast of units of the
Agreement Product for the three (3) year period (including a year-by-year
breakdown) beginning with the Agreement Year following such expired Agreement
Year. Each such sales forecast described above is referred to herein as a "Sales
Forecast."
(b) Supply Forecasts and Minimum Purchases. Within * after the
expiration of each Contract Quarter, commencing with the first Contract Quarter
of the * Agreement Year, the Distributor shall provide to Biomatrix an updated *
supply forecast (the "Supply Forecast") for each country in the Territory. The
Distributor shall be obligated to purchase the quantity of Agreement Product
included for the * quarter of each Supply Forecast. Commencing with the updated
Supply Forecast to be delivered at the beginning of the * Agreement Year, the
Distributor shall not decrease an updated Supply Forecast in any quarter by more
than * from the preceding quarter's forecast.
(c) Minimum Sales. The Distributor hereby agrees that during each
Agreement Year commencing with the * Agreement Year it shall make aggregate
sales of not less than the Minimum Sale Amount for such Agreement Year. The
"Minimum Sale Amount" for any period shall be the minimum number of Treatment
Packs required to be sold during such period pursuant to this Section 9.3(c).
The Minimum Sale Amount for the * Agreement Year shall be determined by the
parties no later than * prior to the commencement of the * Agreement Year,
taking into account reimbursement levels, product price and market and economic
factors. The parties shall determine in good faith the Minimum Sale Amounts for
the * Agreement Year in accordance with the process set forth in Section
8.13(a). Prior to the commencement of each * thereafter during the Initial Term
(and including any extensions thereof in accordance with this Agreement), the
parties shall determine the Minimum Sale Amounts to apply for each year in such
* , and such determination shall be made in good faith in accordance with
Section 8.13(a).
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 29
(d) Firm Orders. The Distributor shall submit a firm purchase order
setting forth the quantities, delivery date and shipping instructions with
respect to each shipment of the Agreement Product, such purchase orders to be
received by Biomatrix at least * prior to the stipulated delivery date * . Each
such firm purchase order shall obligate the Distributor to purchase the full
amount of Agreement Product included on such order, and such order shall be
irrevocable. The Distributor shall not submit any purchase order for fewer than
* Syringes.
(e) Consequences of failure to make Minimum Sales. If the Distributor
fails to sell the Minimum Sale Amount in any "Applicable Period" (in each case
other than if prevented by force majeure (as defined in Section 20) or as a
result of a failure by Biomatrix to supply the Agreement Product in accordance
with Section 9.2(g) or as a result of the violation of the patent or trademark
rights of third parties caused by the marketing and sale of the Agreement
Product or as a result of termination of Reimbursement Approval in France by the
regulatory authorities), then Biomatrix may elect either to (i) * pursuant to
which Biomatrix would either determine to * in the Territory (in which case *
incurred after the * and after such * Agreement Product by the Product
Specialists shall be * for the Agreement Product in the Territory on terms and
conditions acceptable to Biomatrix, or (ii) * or such shorter period as may be
agreed by the parties. For avoidance of doubt, any such * by the Distributor. If
Biomatrix elects to * Biomatrix and the Distributor shall discuss * and shall
discuss such other * required in order to bring this Agreement into compliance
with applicable law (including EU competition law); provided that all of such
discussions shall be conducted in accordance with the provisions of Section
8.13(a) and (b).
For purposes of this paragraph (e), "Applicable Period" shall mean *
Agreement Year and * Agreement Year period thereafter, and the Minimum Sale
Amount for a * Agreement Year period shall be the aggregate of the Minimum Sale
Amounts for each year of such * Agreement Year period.
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 30
(f) Records and audits. The Distributor shall maintain books of account
with respect to its sales of the Agreement Product in the Territory. Biomatrix
shall have the right, not more than once during each calendar year, to have an
independent firm of accountants that is reasonably acceptable to the Distributor
(any "big six" firm being deemed acceptable to the Distributor for this
purpose), selected and retained by Biomatrix to inspect and examine such books
of the Distributor during regular business hours for the purpose of verifying
the Distributor's statements of the aggregate Net Revenues of the Agreement
Product in the Territory and determining the correctness of the Formula Prices.
The cost of each such audit shall be borne by the Distributor; provided, that
Biomatrix shall pay the cost of such audit if as a result of such audit the
Distributor is not required to make any additional payments to Biomatrix. Any
additional payments required as a result of such inspection and examination
shall be immediately paid to Biomatrix and shall bear interest from the date
such amount should otherwise have been paid until the date of actual payment at
the rate per annum set forth in Section 21 hereof.
9.4. SHIPMENT AND DELIVERY; PACKAGING.
Biomatrix shall arrange for shipment and invoicing to the Distributor
of the Agreement Product ordered by the Distributor or any of its Affiliates
acting on its behalf via common carrier, * The Distributor shall pay all
customs, duties, sales taxes and other governmental charges relating to the
importation and sale of the Agreement Product (other than US taxes, if any,
related to importation and sale of the Agreement Product in the Territory), and
shall have all responsibility for storing and clearing the Agreement Product
through all customs and importation requirements. The Distributor shall not
agree to a customs or duty classification or value added or other sales tax
classification for the Agreement Product in the Territory without the consent of
Biomatrix; provided that this provision shall not prohibit the Distributor from
using any such classification if required by a government authority.
9.5. RISK OF LOSS.
Biomatrix shall retain title to, and bear all risk of loss of, or
damage to, all units of the Agreement Product until the Agreement Product has
been delivered to the port of entry within the Territory. The Distributor shall
bear all risk of loss of, or damage to, all units of the Agreement Product after
delivery by Biomatrix to the port of entry in accordance with Section 9.4.
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 31
9.6. ACCEPTANCE.
(a) Notification of Non-Conformity. Each shipment of Agreement Product
from Biomatrix to the Distributor or its Affiliates shall contain such
laboratory and quality control certificates as are necessary to show that the
Agreement Product is in conformity with the Agreement Product Specifications and
Product Approvals. The Distributor shall notify Biomatrix within * of the
receipt of a shipment of the Agreement Product of any apparent non-conformity of
the Agreement Product. If the Distributor fails to so notify Biomatrix, it will
be deemed to have accepted the product; provided that the warranty provided in
Section 9.8 shall survive acceptance of the Agreement Product by the
Distributor.
(b) Consultation and determination of defects. Biomatrix and the
Distributor agree to consult with each other in accordance with the provisions
of Section 8.13(a) in order to resolve the discrepancy between each other's
determinations regarding any possible defect in the Agreement Product. If such
consultation does not resolve the discrepancy, the parties agree to nominate a
reputable independent laboratory, or another independent third party, in each
case acceptable to both parties, that shall carry out tests on representative
samples taken from such shipment, and the results of such tests shall be binding
on the parties. If the results of such tests demonstrate that the Agreement
Product does not meet the Agreement Product Specifications, then Biomatrix shall
pay the cost of such tests; otherwise, the Distributor shall pay the cost of
such tests. In the case of a recall of any Agreement Product required by a
governmental authority, the process described in this paragraph (b) shall not
apply, and the parties shall carry out the requirements of the governmental
authority in accordance with Section 8.12.
(c) Replacement of defective Agreement Products. Biomatrix shall at its
expense and at no further cost to the Distributor replace any such shipment to
the extent that, in accordance with this Section 9.6, it is determined that it
does not conform to the Agreement Product Specifications. All defective units of
the Agreement Product shall be returned to Biomatrix at the address set forth
above, accompanied or preceded by a reasonably detailed statement of the claimed
defect or non-conformity and proof of date of purchase (if available), and
packed and shipped according to instructions provided by Biomatrix. The
shipping, handling and packaging costs of any such returned units of the
Agreement Product shall be borne by Biomatrix.
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 32
9.7. PURCHASE ORDERS.
The provisions of this Agreement shall control over any inconsistent
statement or provisions contained in any document related to this Agreement
passing between the parties hereto including, but not limited to, any purchase
order, acknowledgement, confirmation or notice and shall be incorporated, as
applicable, in the individual sales contracts made by the Distributor.
9.8. LIMITED WARRANTY; LIMITATION ON LIABILITY.
Biomatrix represents and warrants that the Agreement Product supplied
to the Distributor hereunder shall:
(a) conform to the Agreement Product Specifications; and
(b) be manufactured, labelled, packaged and tested (while in
the possession or control of Biomatrix) in accordance with the applicable
Product Approvals therefor and the applicable laws and regulations in the
Territory relating to the manufacture, labelling, packaging and testing of the
Agreement Product.
THE FOREGOING WARRANTY IS THE SOLE AND EXCLUSIVE WARRANTY GIVEN BY
BIOMATRIX WITH RESPECT TO THE AGREEMENT PRODUCT, AND BIOMATRIX GIVES AND MAKES
NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, OTHER THAN THE
FOREGOING. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, NO IMPLIED WARRANTY
OF MERCHANTABILITY, NO IMPLIED WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE,
AND NO IMPLIED WARRANTY ARISING BY USAGE OF TRADE, COURSE OF DEALING OR COURSE
OF PERFORMANCE IS GIVEN OR MADE BY BIOMATRIX OR SHALL ARISE BY OR IN CONNECTION
WITH ANY SALE OR PROVISION OF THE AGREEMENT PRODUCT BY BIOMATRIX, OR THE
DISTRIBUTOR'S USE OR SALE OF THE AGREEMENT PRODUCT, OR BIOMATRIX'S AND/OR THE
DISTRIBUTOR'S CONDUCT IN RELATION THERETO OR TO EACH OTHER. NO REPRESENTATIVE OF
BIOMATRIX IS AUTHORIZED TO GIVE OR MAKE ANY OTHER REPRESENTATION OR WARRANTY OR
TO MODIFY THE FOREGOING WARRANTY IN ANY WAY.
The limited warranty set forth in this Section 9.8 does not apply to any
non-conformity of the Agreement Product resulting from (i) repair, alteration,
misuse, negligence, abuse, accident, mishandling or storage in an improper
environment in each case by any party other than
<PAGE> 33
Biomatrix or its Affiliates or agents or (ii) use, handling, storage or
maintenance other than in accordance with the Agreement Product Specifications.
Biomatrix's sole obligation with respect to units of the Agreement
Product which do not meet the warranty contained herein is limited to
replacement of such units of the Agreement Product, provided that the procedure
set forth in Section 9.6 has been complied with.
BIOMATRIX'S LIABILITY, AND THE EXCLUSIVE REMEDY, IN CONNECTION WITH THE
SALE OR USE OF THE AGREEMENT PRODUCT (WHETHER BASED ON CONTRACT, NEGLIGENCE,
BREACH OF WARRANTY, STRICT LIABILITY OR ANY OTHER LEGAL THEORY), SHALL BE
STRICTLY LIMITED TO BIOMATRIX'S OBLIGATIONS AS SPECIFICALLY AND EXPRESSLY
PROVIDED IN SECTIONS 9.6 AND 9.8 AND IN SECTION 10 BELOW. EXCEPT AS SPECIFICALLY
PROVIDED IN SECTIONS 9.6 AND 9.8 AND IN SECTION 10 BELOW, BIOMATRIX SHALL HAVE
NO LIABILITY, OBLIGATION OR RESPONSIBILITY OF ANY KIND, IN ANY WAY OR TO ANY
EXTENT, FOR ANY DAMAGES, LOSSES, COSTS, EXPENSES OR LIABILITIES FOR ANY
REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE AGREEMENT PRODUCT OR
THE PERFORMANCE THEREOF, OR ARISING IN ANY WAY IN CONNECTION WITH THE PURCHASE
OR USE OR INABILITY TO USE THE AGREEMENT PRODUCT, EVEN IF BIOMATRIX HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. SUBJECT TO SECTION 10 BELOW, IN NO
EVENT WHATSOEVER SHALL BIOMATRIX HAVE ANY LIABILITY, OBLIGATION OR
RESPONSIBILITY TO THE DISTRIBUTOR OR ANY OTHER PERSON FOR ANY INDIRECT,
INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES ARISING IN ANY
WAY IN CONNECTION WITH THE AGREEMENT PRODUCT OR ITS SALE OR USE.
10. INDEMNIFICATION; LIMITATION ON LIABILITY
10.1. INDEMNIFICATION FROM THE DISTRIBUTOR.
Subject to the provisions of Section 10.3, the Distributor shall
defend, indemnify and hold Biomatrix and its Affiliates and their respective
directors, officers, agents and employees harmless from and against any and all
liabilities, claims, damages and expenses (including without limitation actual
court costs and reasonable attorneys' fees regardless of outcome) resulting from
or arising out of or in connection with:
(a) any failure or alleged failure by the Distributor or any of its
Affiliates to act in accordance with the terms of this Agreement and/or any
applicable laws and regulations in the Territory in connection with the
Agreement Product, including without limitation any unauthorized
representations, warranties or guarantees given by the Distributor;
(b) any activities of the Distributor or any of its Affiliates
relating to the promotion, marketing, sale and distribution of the Agreement
Product; and/or
(c) any breach by the Distributor of any representation, warranty or
covenant made by it in this Agreement.
<PAGE> 34
10.2. INDEMNIFICATION FROM BIOMATRIX.
Subject to the provisions of Section 10.3, Biomatrix shall defend,
indemnify and hold the Distributor and its Affiliates and their respective
directors, officers, agents and employees harmless from and against any and all
liabilities, claims, damages and expenses (including without limitation actual
court costs and reasonable attorneys' fees regardless of outcome) resulting from
or arising out of or in connection with:
(a) * resulting from the * of the Agreement Product in the Territory
in accordance with this Agreement;
(b) * of the Agreement Product in accordance with the Agreement *
did not arise or result from the improper use, administration, storage or
handling of the Agreement Product by a person other than Biomatrix;
(c) any failure or alleged failure by Biomatrix or any of its
Affiliates to act in accordance with the terms of this Agreement; and/or
(d) any breach by Biomatrix of any representation, warranty or
covenant made by it in this Agreement.
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 35
10.3. LIMITATION ON LIABILITY.
NOTWITHSTANDING ANY PROVISION TO THE CONTRARY IN SECTIONS 10.1 AND 10.2
ABOVE, OR ANY OTHER PROVISION OF THIS AGREEMENT, IN NO EVENT (INCLUDING THE
FAULT, NEGLIGENCE OR STRICT LIABILITY OF EITHER PARTY) SHALL EITHER PARTY BE
LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL,
PUNITIVE OR EXEMPLARY DAMAGES; PROVIDED, NOTHING IN THIS SECTION 10.3 SHALL
LIMIT THE OBLIGATION OF A PARTY UNDER THIS SECTION 10 RELATING TO A THIRD PARTY
CLAIM.
10.4 INDEMNIFICATION PROCEDURE.
The party claiming indemnification ("Indemnitee"), after being advised
of any assertions of any such third party claims or suits or upon the bringing
or filing of such claims or suits by any third party against the Indemnitee,
shall promptly notify the party from which indemnification is sought
("Indemnitor") thereof; provided, that the failure to promptly notify shall not
affect the Indemnitor's obligations hereunder except to the extent the
Indemnitor is prejudiced by the delay in notification. The Indemnitee shall
permit the Indemnitor's attorneys to control the defense of such claims or suits
at the Indemnitor's cost. The Indemnitee shall co-operate with the Indemnitor in
the defense of such claims or suits. The parties agree that there shall be no
settlements, whether agreed to in court or out of court, without the prior
written consent of the Indemnitor.
11. REPRESENTATIONS OF BIOMATRIX
Biomatrix represents, warrants and covenants as follows:
11.1. AUTHORITY.
Biomatrix is a corporation duly organized and validly existing under
the laws of the State of Delaware with the full power to conduct its affairs as
currently conducted and contemplated hereunder. All necessary action has been
taken to enable it to execute and deliver this Agreement and perform its
obligations hereunder.
<PAGE> 36
11.2. ENFORCEABILITY.
This Agreement is a valid and binding obligation of Biomatrix
enforceable in accordance with its terms. Biomatrix has the unencumbered right
to enter into this Agreement and to fulfill its duties hereunder. It is not and
will not become a party to any agreement in conflict herewith. Accordingly,
Biomatrix has the right to appoint the Distributor as the exclusive distributor
of the Agreement Product in the Territory in accordance with the terms of this
Agreement and such appointment will not constitute a breach of any existing
contractual or other arrangements between Biomatrix and any Affiliated or
non-Affiliated third party, nor shall it infringe the rights of any Affiliated
or non-Affiliated third party.
11.3. NO CONSENTS.
No approval, consent, order, authorization or license by, giving notice
to or taking any other action with respect to, any governmental or regulatory
authority is required in connection with the execution and delivery of this
Agreement by Biomatrix and the performance by Biomatrix of its obligations
hereunder, other than the Product and Reimbursement Approvals contemplated
herein.
11.4. INFORMATION.
The data and other information provided in writing by Biomatrix to the
Distributor pursuant to Section 15.1(b) does not contain any untrue statement of
a material fact.
11.5. INTELLECTUAL PROPERTY.
To its knowledge, the Patents and the Trademarks in the Territory do
not infringe the rights of third parties.
11.6. CE MARK.
The Agreement Product has received a Certificate (EC Design-Examination
Certificate Annex II-4) approving the Agreement Product as a device with a CE
mark. Biomatrix will use commercially reasonable efforts at its cost to maintain
and renew the approval represented by such Certificate.
<PAGE> 37
12. REPRESENTATIONS OF THE DISTRIBUTOR
The Distributor represents, warrants and covenants as follows:
12.1. AUTHORITY.
The Distributor is a company duly organized and validly existing under
the laws of the Republic of France, with full power to conduct its affairs as
currently conducted and contemplated hereunder. All necessary action has been
taken to enable it to execute and deliver this Agreement and perform its
obligations hereunder.
12.2. ENFORCEABILITY.
This Agreement is the Distributor's valid and binding obligation
enforceable in accordance with its terms. The Distributor has the unencumbered
right to enter into this Agreement and to fulfill its obligations hereunder. It
is not and will not become a party to any agreement in conflict herewith.
Accordingly, the Distributor has the right to act as the exclusive distributor
of the Agreement Product in the Territory in accordance with the terms of this
Agreement and the performance of its obligations hereunder will not constitute a
breach of any existing contractual or other arrangements between the Distributor
and any Affiliated or non-Affiliated third party, nor shall it infringe the
rights of any Affiliated or non-Affiliated third party.
12.3. NO CONSENTS.
No approval, consent, order, authorization or license by, giving notice
to or taking any other action with respect to any governmental or regulatory
authority is required in connection with the execution and delivery of this
Agreement by the Distributor and the performance by the Distributor of its
obligations hereunder, other than the Product and Reimbursement Approvals
contemplated herein.
12.4. LOCAL LAWS.
The Distributor shall carry out its responsibilities and obligations
hereunder in accordance with all applicable laws and regulations in the
Territory.
<PAGE> 38
13. INSURANCE
Each party hereto shall (i) obtain and maintain such insurance
policies, including product liability insurance, as are adequate to cover its
respective obligations hereunder and which are consistent with normal business
practices of prudent companies similarly situated and (ii) provide the other
party, upon request, with certificates of insurance confirming the existence of
such insurance policies.
14. INFRINGEMENT OF PATENTS AND TRADEMARKS.
14.1 NOTIFICATION.
Each of the Distributor and Biomatrix will notify the other party in
writing of any infringement of a Patent or Trademark or unauthorized disclosure
or use of any Confidential Information in the Territory within * after it
becomes aware of such infringement or unauthorized disclosure.
14.2 INFRINGEMENT ACTIONS.
Biomatrix shall have the exclusive right (after consultation with the
Distributor) at its own cost to take all legal action in the Territory it deems
necessary or advisable to eliminate or minimize the consequences of any
infringement of a Patent or Trademark in the Territory. For the purpose of
taking any such legal action, Biomatrix shall have the right, subject to the
Distributor's prior written consent (which consent shall not be unreasonably
withheld or delayed) to use the name of the Distributor and/or any local
Affiliate of the Distributor as plaintiff, either solely or jointly in
accordance with the applicable rules of procedure. The Distributor shall
promptly furnish Biomatrix with whatever written authority may be required in
order to enable Biomatrix to use the Distributor's name or that of its Affiliate
in connection with any such legal action, and shall otherwise cooperate fully
and promptly with Biomatrix in connection with any such action, and shall cause
its local Affiliate to cooperate and assist Biomatrix in taking any such legal
action. Biomatrix shall permit the Distributor to participate at its own cost in
any legal action in the Territory brought by Biomatrix to eliminate or minimize
the consequences of any infringement of a Patent or Trademark in the Territory;
provided that Biomatrix shall maintain the right to control the prosecution of
such action. All proceeds realized upon any judgement or settlement regarding
such action (net of direct out-of-pocket expenses relating thereto) shall be *
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 39
* Notwithstanding the foregoing, if Biomatrix (i) notifies the
Distributor in writing that it does not intend to exercise its rights to take
legal action in the Territory to eliminate or minimize the consequences of an
infringement of a Patent or Trademark in the Territory, and (ii) authorizes the
Distributor to pursue such legal action, then the Distributor shall be entitled,
at its own cost and expense, to take such legal action, and Biomatrix shall
cooperate with the Distributor in connection therewith to the same extent and
upon the same terms as the Distributor is required to cooperate with Biomatrix
when Biomatrix exercises its rights under this Section 14.2; provided, however,
that Biomatrix shall be entitled to an amount equal to * of the amount (net of
the Distributor's direct out-of-pocket expenses in prosecuting such action) of
any judgement or settlement payable to the Distributor.
15. REGULATORY ACTIVITIES AND REIMBURSEMENT APPROVALS
15.1. GENERAL.
(a) Approvals. The Distributor shall use commercially reasonable
efforts at its cost in cooperation with Biomatrix and (to the extent required by
law but solely for purposes of obtaining Reimbursement Approval) as Biomatrix's
agent (i) to obtain Reimbursement Approvals in France as soon as possible after
the Effective Date, (ii) to obtain all necessary Product Approvals and all other
Reimbursement Approvals in the Territory (other than the approval referred to in
Section 11.6), and (ii) thereafter to maintain all Product Approvals and
Reimbursement Approvals in effect (other than the approval referred to in
Section 11.6) throughout the term of this Agreement and to obtain, if possible,
increases in the level of reimbursement allowed in the Reimbursement Approvals
from time to time. All Reimbursement Approvals shall result in prices to third
parties for the Agreement Product and in levels of patient reimbursement that
are as optimal as possible. The Distributor agrees not to sell the Agreement
Product in a country in the Territory until such time as all necessary Product
Approvals with respect to such country have been obtained.
(b) * as soon as reasonably practicable after written request by *
related to the Agreement Product necessary to * in the Territory and in carrying
out its other obligations under this Agreement. The Distributor in cooperation
with Biomatrix shall * as may be necessary to meet its obligations under this
Agreement.
*
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 40
(c) Review and Assistance by Biomatrix. Biomatrix shall be entitled
generally to oversee the strategy and content of all applications for Product
and Reimbursement Approvals and the content of all such applications shall be
subject to Biomatrix's written approval prior to submission to any regulatory
authority or to any other third party, * . All Product Approvals and
Reimbursement Approvals shall be the exclusive property of and held in the name
of Biomatrix except to the extent that applicable law requires that such
approvals be held in the name of the Distributor, or unless otherwise agreed in
writing by the parties.
(d) Mutual support. The Distributor and Biomatrix shall promptly
provide reasonable advice and assistance to each other as may be necessary to
obtain and maintain Product Approvals and, if applicable, satisfactory
Reimbursement Approvals for the Agreement Product.
(e) Transfer of approvals. Except to the extent necessary to give
effect to the provision of the first sentence of Section 3.2(b), in the event
that the Product Approvals and the Reimbursement Approvals (if any) relating to
the Agreement Product in any country in the Territory is in the name of the
Distributor or any of its Affiliates, it shall be transferred to Biomatrix
immediately upon termination of the Agreement.
(f) Reporting on Agreement Product. During the term of this Agreement,
each party shall immediately notify the other in writing in the event that such
party becomes aware of any failure of the Agreement Product to comply with any
of the requirements therefor specified in any Product Approval.
(g) Ongoing information exchange. Each party shall keep the other
advised of regulatory interactions, activities and correspondence and the
registration status of the Agreement Product on a quarterly basis, except that
matters requiring more immediate attention shall be communicated as soon as
practicable.
15.2. CLINICAL TRIALS; PUBLICATION OF RESULTS.
(a) The Distributor shall be responsible at its own cost for conducting
and managing a clinical program to be conducted in France pursuant to a plan and
schedule to be prepared by the Distributor promptly after the Effective Date in
cooperation with Biomatrix, such plan to include
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 41
an expenditure by the Distributor during the * Agreement Years in the range of
*, and during the * Agreement Years in the range of an additional * . The final
version of such plan and schedule shall be approved by the parties in accordance
with the provisions of Section 8.13(a), and shall include any clinical trials
which the Distributor may be required to undertake in order to obtain Product
Approval and Reimbursement Approval in the Territory; provided that the
protocols for all such clinical trials shall be subject to Biomatrix's prior
written approval and Biomatrix shall have the right to review the performance of
any such clinical studies.
*
(b) The Distributor shall provide the completed data resulting from all
clinical trials conducted in accordance with this Section 15.2 to Biomatrix for
analysis, and Biomatrix shall prepare the final reports relating to such
clinical trial data in an agreed format. Biomatrix and its Affiliates shall be
free to use the results of any or all such clinical trials in the promotion,
marketing and product licensing of the Agreement Product outside the Territory.
The results of any such studies will not be published or publicized in any way
without the prior written consent of Biomatrix, such consent not to be
unreasonably withheld. If Biomatrix has consented to publication, Biomatrix and
the Distributors shall jointly prepare the manuscript and select the journal for
publication.
15.3. WITHDRAWAL OF PRODUCT FOR SAFETY REASONS.
If a regulatory authority in a country in the Territory withdraws the
approval to sell the Agreement Product in such country for product safety
reasons, the Distributor shall not be obligated to sell the Agreement Product in
such country from the date of such withdrawal and until the Distributor is again
authorized to sell Agreement Product in such country, and Biomatrix shall not be
obligated to supply the Agreement Product to the Distributor in such country for
such period. If such a withdrawal decision is final and not appealable, this
Agreement shall terminate with respect to such country.
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 42
16. FURTHER ASSURANCES
The parties hereto agree to execute such further or other documents and
assurances as are necessary from time to time in order to give effect to the
provisions of this Agreement.
17. ASSIGNMENT
17.1. GENERAL.
The rights and obligations of the parties hereto shall inure to the
benefit of and shall be binding upon the authorized successors and permitted
assigns of each party. Except to the extent permitted by Section 17.2, neither
party may take any of the following actions (collectively referred to herein as
an "Assignment"): (i) assign a material part of its rights or obligations under
this Agreement, (ii) subcontract, sublicense or otherwise delegate a material
part of its rights or obligations under this Agreement, or (iii) designate
another person to perform all or a material part of its obligations under this
Agreement (except in the ordinary course of business), without the prior written
consent of the other party, except to a successor of the entire business of the
Distributor, by merger, amalgamation or otherwise.
17.2. PARTICIPATION BY AFFILIATES.
It is acknowledged and understood that each of the parties hereto may
from time to time perform some or all of its obligations hereunder through one
or more of its Affiliates. In that regard, each of the parties agrees (i) not to
permit a person that is not an Affiliate to perform any of its obligations
hereunder (except to the extent not prohibited by Section 17.1), (ii) if the
participation of the Affiliate is not in the ordinary course of business, to
notify the other party in writing prior to the participation of the Affiliate in
this Agreement, describing the Affiliate and its expected involvement hereunder,
(iii) to ensure that its Affiliates comply with all of the provisions hereof,
(iv) that the other party hereto will not be in a direct contractual
relationship with such Affiliate and (v) that the party involving such Affiliate
shall be responsible to the other party hereto, both as primary obligor and as
guarantor, for the performance of all of its obligations hereunder, and for the
conduct of its Affiliates.
<PAGE> 43
18. GOVERNING LAW; ARBITRATION; INJUNCTIVE RELIEF
18.1. GOVERNING LAW.
This Agreement and the legal relations between the parties in
connection herewith shall be governed by and construed in accordance with the
internal and substantive laws of the State of New Jersey, United States of
America. The parties hereby agree that the United Nations Convention on
Contracts for the International Sale of Goods shall not apply to this Agreement
or any other document contemplated hereby.
18.2. ARBITRATION.
In the event of any dispute touching or concerning this Agreement
(other than a matter required by the terms hereof to be referred to the process
set forth in Section 8.13 (a) and (b)), the parties hereby agree that they shall
submit the dispute for arbitration in Paris, France under the Rules for
Conciliation and Arbitration of the International Chamber of Commerce in effect
on the Effective Date (the "Rules") by no more than three (3) arbitrators
appointed in accordance with said Rules. Any decision of such arbitrators shall
be final and binding upon the parties. The arbitrators shall apply the governing
law set forth in this Section and such arbitration shall be conducted in the
English language. Judgment upon an award rendered by the arbitrators may be
entered in any court having jurisdiction thereof.
18.3. INJUNCTIVE RELIEF.
Each of the parties hereto acknowledges and agrees that damages will
not be an adequate remedy for any material breach or violation of Sections 6 or
7.1 of this Agreement if such material breach or violation would cause immediate
and irreparable harm (an "Irreparable Breach"). Accordingly, notwithstanding the
provisions of Section 18.2 hereof to the contrary, in the event of a threatened
or ongoing Irreparable Breach, each party hereto shall be entitled to seek, in
any state or federal court in the State of New Jersey or in any court in the
Republic of France, equitable relief of a kind appropriate in light of the
nature of the ongoing threatened Irreparable Breach, which relief may include,
without limitation, specific performance or injunctive relief; provided,
however, that if the party bringing such action is unsuccessful in obtaining the
relief sought, the moving party shall pay the non-moving party's reasonable
costs, including attorney's fees, incurred in connection with defending such
action. Such remedies shall
<PAGE> 44
not be the parties' exclusive remedies, but shall be in addition to all other
remedies provided in this Agreement.
19. SEVERABILITY
In the event that any provision of this Agreement shall be held by a
court of competent jurisdiction or by any governmental body to be invalid or
unenforceable, such provision shall be deemed severable and the remaining parts
and provisions of this Agreement shall remain in full force and effect.
20. FORCE MAJEURE
Each of the parties shall be excused from the performance of its
obligations hereunder in the event such performance is prevented by force
majeure, and such excuse shall continue as long as the condition constituting
such force majeure continues. For the purpose of this Agreement, force majeure
is defined as contingencies beyond the reasonable control of either party and
not anticipated at the time of this Agreement, including, without limitation,
acts of God, judicial or regulatory action, war, civil commotion, destruction of
production facilities or materials by fire, earthquake or storm and labor
disturbances or strikes (whether or not any such labor disturbance or strike is
within the power of the affected party to settle). The party affected by force
majeure shall provide the other party with full particulars thereof as soon as
it becomes aware of the same (including its best estimate of the likely extent
and duration of the interference with its activities), and will use its best
endeavors to overcome the difficulties created thereby and to resume
performance of its obligations as soon as practicable.
21. INTEREST
Any overdue amounts payable by either party hereunder shall bear
interest compounded monthly at the prime lending rate for US Dollars published
from time to time in The Wall Street Journal plus *
per annum, or, if lower, the highest rate permissible by applicable law, from
the due date until the date of payment.
22. NO PARTNERSHIP OR AGENCY; NO THIRD PARTY BENEFICIARIES
This Agreement and the relations hereby established by and between
Biomatrix and the Distributor do not constitute a partnership, joint venture,
agency (except to the limited extent
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 45
provided in Section 15.1(a)) or contract of employment between them. This
Agreement is a bilateral agreement between the Distributor and Biomatrix, and no
third parties (including Affiliates of the parties hereto) shall have any rights
hereunder.
23. NOTICES
All communications in connection with this Agreement shall be in
writing and sent by postage prepaid first class mail, courier, or telefax, and
if relating to default, late payment or termination, by certified mail, return
receipt requested, telefax or courier, addressed to each party at the address
above, in the case of Biomatrix, Attn: Chief Executive Officer, with a copy to:
Justin P. Morreale, Esq., Bingham, Dana & Gould, 150 Federal Street, Boston,
Massachusetts 02110, U.S.A., and in the case of the Distributor Attn: Chief
Executive Officer, or to such other address as the addressee shall last have
designated by notice to the communicating party. The date of giving any notice
shall be the date of its actual receipt.
24. EU REGULATIONS
It is the intention of the parties hereto that this Agreement shall at
all times qualify for the exemption from the provisions of Article 85(1) of the
Treaty of Rome dated 25 March, 1957, as amended, which either (a) is available
under EEC Regulation Number 1983/83, or (b) may subsequently be available under
any successor regulation or regulations thereto. In the event that any provision
of this Agreement is deemed to violate the conditions for qualifying for the
exemption, set out in whichever of those regulations may be in effect at the
relevant time, or if any such regulation is amended after the date of this
Agreement so as to cause this Agreement to fail to qualify for the exemption,
the parties hereto agree that they will, as soon as it is practicable to do so,
enter into good faith negotiations to amend this Agreement as necessary in order
to re-qualify for the exemption. If those negotiations are not successfully
concluded within a reasonable time (not to exceed ninety (90) days, or such
other period as is agreed upon in writing by the parties hereto, after the
relevant regulation is amended), either party may terminate this Agreement upon
thirty (30) days' prior written notice to the other party.
25. SURVIVAL
The provisions of Sections 3.2, 3.6, 3.7, 3.8, 7.1, 7.2, 8.2, 9.5, 9.8,
10.1, 10.2, 10.3, 10.4 and 15.1(e) of this Agreement shall survive the
termination or expiration of this Agreement (as the case may be) and shall
thereafter remain in full force and effect. The provisions of this Agreement
that do not survive termination or expiration hereof (as the case may be) shall,
<PAGE> 46
nonetheless, be controlling on, and shall be used in construing and interpreting
the rights and obligations of the parties hereto with regard to, any dispute,
controversy or claim which may arise under, out of, or in connection with this
Agreement.
26. MISCELLANEOUS
26.1. ENTIRE AGREEMENT.
This Agreement sets forth the entire agreement between the parties with
respect to the transactions and arrangements contemplated hereby and supersedes
all prior oral or written arrangements, including without limitation the letter
of intent dated 1 August 1996 by and between the parties and the term sheet
attached thereto.
26.2. AMENDMENTS.
This Agreement may be modified or amended only by a written instrument
executed and delivered by both parties.
26.3. NO WAIVER.
None of the provisions of this Agreement shall be deemed to have been
waived by any act or acquiescence on the part of either party except by an
instrument in writing signed and delivered by the party executing the waiver.
26.4. COUNTERPARTS.
This Agreement may be executed in several identical counterparts, each
of which shall be an original, but all of which constitute one instrument, and
in making proof of this Agreement it shall not be necessary to produce or
account for more than one such counterpart.
26.5. HEADINGS.
The title of this Agreement and the section headings contained herein
are for convenience of reference only and shall not define or limit the
provisions hereof.
<PAGE> 47
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date and year first above written.
BOEHRINGER INGELHEIM FRANCE, S.A.
By: /s/ Paul Bonnabel
-----------------------------
Name: Paul Bonnabel
Title: Director
By: /s/ D. Mangeot
-----------------------------
Name: D. Mangeot
Title: Gerant (Manager)
BIOMATRIX, INC.
By: /s/ Endre A. Balazs
-----------------------------
Name: Endre A. Balazs
Title: Chief Executive Officer
<PAGE> 48
EXHIBITS
--------
Exhibit A - Agreement Product Specifications
Exhibit B - Patents and Trademarks
Exhibit C - Legends
Exhibit D - Sales Forecasts and Sample Volumes
Exhibit E - Promotional Plan and Budget
<PAGE> 49
EXHIBIT A
---------
Agreement Product Specifications
Specification of Synvisc(R)
(hylan G-F 20)
Tests Procedures Specifications
- ----- ---------- --------------
*
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 50
EXHIBIT B
---------
I. SYNVISC RELATED FRENCH PATENTS
*
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 51
EXHIBIT C
---------
Legends
<PAGE> 52
EXHIBIT D
---------
Sales Forecasts and Sample Volumes*
Non Reimbursement Scenario
Year 1 Year 2 Year 3
------ ------ ------
Sales (#Treatments) * * *
Samples * * *
Reimbursement
Year 1 Year 2 Year 3
------ ------ ------
Sales (#Treatments) * * *
* see Section 9.3(a).
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 53
EXHIBIT E
Preliminary Promotion Budget and Schedule
(INVESTMENT PLAN FOR SYNVISC)
Hypothesis: Non reimbursed; * per treatment
(All Amounts in FF000)
- --------------------------------------------------------------------------------
1997 1998 1999 2000
Awareness Program * * * *
Congresses
Symposium
Physician Training * * * *
Training Sessions
Training Tools
GPs Information
Phase IV * * * *
TIPS
Scientific studies
PMS (Patient database) * * * *
Biomatrix Synvisc Specialists * * * *
Patient Services * * * *
Patient Activities
Patient Refund Plan
Marketing/Ad Agencies * * * *
Press/Advertising * * * *
Samples * * * *
- --------------------------------------------------------------------------------
Total Costs per year * * * *
Cumulative Costs
- --------------------------------------------------------------------------------
*Confidential portions have been omitted and filed separately with the
Commission.
<PAGE> 54
Preliminary Promotion Budget and Schedule
(INVESTMENT PLAN FOR SYNVISC)
Hypothesis Reimbursed; * per treatment
(All Amounts in FF000)
- --------------------------------------------------------------------------------
1997 1998 1999 2000
Awareness Program * * * *
Congresses
Symposium
Physician Training * * * *
Training Sessions
Training Tools
GPs Information
Phase IV * * * *
TIPS
Scientific studies
PMS (Patient database) * * * *
Biomatrix Synvisc Specialists * * * *
Patient Services * * * *
Patient Activities
Patient Refund Plan
Marketing/Ad Agencies * * * *
Press/Advertising * * * *
Sampling * * * *
- --------------------------------------------------------------------------------
Total Costs per Year * * * *
Cumulative Costs
- --------------------------------------------------------------------------------
*Confidential portions have been omitted and filed separately with the
Commission.
